2012. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics. 67, 3 (Jan. 2012), 283–287. DOI:https://doi.org/10.6061/clinics/2012(03)14.